VivoSeq
Other

Mastitis

5

Pipeline Programs↗

0

Active Trials↗

1

Companies Involved↗

Mastitis is an early-stage landscape with 5 programs across 1 company. The most active players are Eli Lilly. 2 therapies are approved with 1 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

27/100

Pipeline Velocity

0/100

Mech. Concentration

50/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Eli Lilly logo

Eli Lilly

1 program

Approved

Pipeline

Programs by Phase

Analysis

Trial Status

4

clinical trials

Unknown status3 · 75%
Completed1 · 25%

Clinical Trials

Trial Activity

Use of Probiotic Lactobacilli for the Treatment of Lactational Mastitis
Completed·UUniversidad Complutense de Madrid·Phase 2/3·NCT00716183·300 enrolled
The Effect of Chinese Herbal Medicine for Reducing the Application of Antibiotics in the Treatment of Acute Mastitis
Unknown status·—·Phase 2/3·NCT03756324·306 enrolled
A Single Arm Study of Traditional Chinese Medicine for Plasma Cell Mastitis
Unknown status·SShengjing Hospital·Phase 2·NCT05530226·50 enrolled
Study of a Probiotic Strain to Prevent Mastitis and to Eradicate GBS Colonization
Unknown status·UUniversidad Complutense de Madrid·Phase 1/2·NCT01505361·100 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)